About the publication
Understanding what changes next in European life sciences.
Independent, operator-led analysis of the commercial models, technologies and market forces reshaping pharma, MedTech and health technology.
The difficult part is not spotting change. It is knowing what it means.
Life-sciences companies rarely struggle for ideas. They struggle to turn strategy, technology and evidence into coordinated commercial action.
Disrupting Healthcare examines how pharmaceutical, MedTech and health-technology companies are redesigning their commercial models for a market shaped by AI, new evidence requirements, changing access conditions and rising execution complexity.
The focus is primarily European, with global developments included when they materially affect European leaders.
The editorial test
“Does this help a senior leader understand what has changed, why it matters and what to do next?”
If the answer is no, it does not belong here.
What you’ll find here
Signal, depth and practical consequence.
01 / WEEKLY SIGNAL
The story beneath the headlines
A concise weekly synthesis of the developments that matter—and what they mean for senior life-sciences leaders.
02 / ANALYSIS
The operating model in focus
Long-form examination of commercial models, AI adoption, customer engagement, market access, data infrastructure and organizational change.
03 / OPERATORS’ LENS
What leaders should do next
Practical perspective on what to reconsider, where execution is likely to fail and which capabilities can create an advantage.
Editor’s perspective
“The aim is not to publish more healthcare news. It is to provide a clearer view of how the industry is changing, and what operators should do about it.”
PIOTR WRZOSINSKI · EDITOR
About the editor
Piotr Wrzosinski
Disrupting Healthcare is written and curated by Piotr Wrzosinski, a life-sciences commercial transformation leader with more than 20 years of experience across BD, Roche, Janssen/J&J, Pfizer, Accenture and IQVIA.
At BD, he leads EMEA commercial transformation infrastructure across more than 30 markets, connecting operating-model design, governance, customer engagement and cross-market execution.
His perspective combines experience from pharmaceutical and MedTech organizations with consulting and transformation leadership. He writes independently about commercial operating models, AI, market access and life-sciences execution in Europe.
Editorial principles
Evidence first. Interpretation clearly marked.
Disrupting Healthcare distinguishes reported facts from editorial interpretation and links material claims to original or authoritative sources wherever possible.
- Primary evidence where possible. Company disclosures, regulators, peer-reviewed research and authoritative datasets take priority over recycled commentary.
- Interpretation stays visible. Forward-looking conclusions are presented as analysis, not disguised as fact.
- Corrections are transparent. When evidence changes, the published record changes with it.
- No paid editorial influence. The publication does not accept sponsored content or paid placement.
The publication is independently produced. The views expressed are Piotr’s own and do not represent those of his employer or any organization with which he has worked. Nothing published here constitutes medical, legal or financial advice.
Contact
Start a serious conversation.
For speaking engagements, interviews, editorial conversations or senior-level exchanges on life-sciences commercial transformation.